KR100589872B1 - 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 - Google Patents

8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 Download PDF

Info

Publication number
KR100589872B1
KR100589872B1 KR1019997011137A KR19997011137A KR100589872B1 KR 100589872 B1 KR100589872 B1 KR 100589872B1 KR 1019997011137 A KR1019997011137 A KR 1019997011137A KR 19997011137 A KR19997011137 A KR 19997011137A KR 100589872 B1 KR100589872 B1 KR 100589872B1
Authority
KR
South Korea
Prior art keywords
azabicyclo
oct
ene
methyl
thienyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997011137A
Other languages
English (en)
Korean (ko)
Other versions
KR20010013154A (ko
Inventor
페터스단
올센군나르엠.
니엘센시몬펠트백
니엘센엘세벳외스테르가아르트
Original Assignee
뉴로서치 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로서치 에이/에스 filed Critical 뉴로서치 에이/에스
Publication of KR20010013154A publication Critical patent/KR20010013154A/ko
Application granted granted Critical
Publication of KR100589872B1 publication Critical patent/KR100589872B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1019997011137A 1997-05-30 1998-05-29 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 Expired - Fee Related KR100589872B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DK62797 1997-05-30
DK0627/97 1997-05-30
DK1502/97 1997-12-19
DK150297 1997-12-19
DK40898 1998-03-24
DK0408/98 1998-03-24
DK0534/98 1998-04-16
DK53498 1998-04-16
PCT/DK1998/000225 WO1998054181A1 (en) 1997-05-30 1998-05-29 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors

Publications (2)

Publication Number Publication Date
KR20010013154A KR20010013154A (ko) 2001-02-26
KR100589872B1 true KR100589872B1 (ko) 2006-06-15

Family

ID=27439314

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997011137A Expired - Fee Related KR100589872B1 (ko) 1997-05-30 1998-05-29 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법

Country Status (22)

Country Link
US (2) US6645977B1 (https=)
EP (1) EP0984965B1 (https=)
JP (1) JP4447663B2 (https=)
KR (1) KR100589872B1 (https=)
CN (1) CN1157392C (https=)
AT (1) ATE267199T1 (https=)
AU (1) AU745964B2 (https=)
BR (1) BR9809697A (https=)
CA (1) CA2289574C (https=)
CZ (1) CZ298824B6 (https=)
DE (1) DE69823994T2 (https=)
DK (1) DK0984965T3 (https=)
EE (1) EE04057B1 (https=)
HU (1) HUP0002713A3 (https=)
IL (2) IL132437A0 (https=)
IS (1) IS2092B (https=)
NO (1) NO325513B1 (https=)
NZ (1) NZ500642A (https=)
RU (1) RU2186780C2 (https=)
SK (1) SK284994B6 (https=)
TR (1) TR199902942T2 (https=)
WO (1) WO1998054181A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0944626A4 (en) * 1996-12-02 2002-09-04 Univ Georgetown TROPANDERIVATIVES AND METHOD FOR YOUR SYNTHESIS
CA2335336A1 (en) 1998-06-19 1999-12-23 James Edmund Audia Inhibition of serotonin reuptake
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
JP2002531456A (ja) 1998-11-27 2002-09-24 ニューロサーチ、アクティーゼルスカブ ８−アザビシクロ〔３．２．１〕オクト−２−エン及び−オクタン誘導体
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
AU2278700A (en) 1999-01-28 2000-08-18 Neurosearch A/S Novel azabicyclo derivatives and their use
TR200102162T2 (tr) * 1999-01-29 2001-12-21 Abbott Laboratories Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler.
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
EP1177196B1 (en) * 1999-05-04 2004-03-10 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
MY137020A (en) * 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
ATE287888T1 (de) * 2000-07-04 2005-02-15 Neurosearch As Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
JP4312456B2 (ja) * 2000-10-13 2009-08-12 ニューロサーチ、アクティーゼルスカブ ニコチン性レセプターアゴニスト及びモノアミン作動性物質の組み合わせ作用による情動障害の治療法
HUP0402289A2 (hu) * 2001-10-02 2005-02-28 Pharmacia & Upjohn Company Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
ATE401334T1 (de) * 2002-05-07 2008-08-15 Neurosearch As Neue azacyclische ethinylderivate
GB2398636A (en) * 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
ES2305735T3 (es) * 2003-02-28 2008-11-01 Schering Corporation Biariltetrahidroisoquinolin-piperidinas como antagonistas del receptor de mch selectivos, para el tratamiento de obesidad y trastornos relacionados.
JP3910627B2 (ja) 2003-03-12 2007-04-25 ファイザー・プロダクツ・インク ピリジルオキシメチルおよびベンゾイソオキサゾールのアザビシクロ環の誘導体
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
DE602006019561D1 (de) 2005-02-16 2011-02-24 Neurosearch As Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
KR20070116867A (ko) * 2005-04-08 2007-12-11 뉴로서치 에이/에스 (+)- 및(-)-8-알킬-3-(트리플루오르알킬설포닐옥시)-8-아자바이사이클(3.2.1)옥트-2-엔
FR2889701B1 (fr) 2005-08-12 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.
CA2632642A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
CN101379063A (zh) 2006-02-10 2009-03-04 神经研究公司 3,9-二氮杂双环[3.3.1]壬烷衍生物及其作为单胺神经递质再摄取抑制剂的用途
AU2007213670A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2007213671A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3-heteroaryl- 3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
CN101466376A (zh) * 2006-06-12 2009-06-24 辉瑞产品公司 用于提高免疫重建并治疗hiv患者的机会感染的ccr5拮抗剂
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
EP2676956A1 (en) * 2008-08-01 2013-12-25 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
CN102216295A (zh) * 2008-11-18 2011-10-12 神经研究公司 8-氮杂双环[3.2.1]辛-2-烯衍生物及其作为单胺神经递质再摄取抑制剂的用途
KR20180011888A (ko) 2008-11-19 2018-02-02 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PE20120324A1 (es) * 2009-05-11 2012-04-17 Envivo Pharmaceuticals Inc Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
CA2787063C (en) 2010-01-11 2018-11-27 Astraea Therapeutics, Llc Nicotinic acetylcholine receptor modulators
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
WO2014011768A1 (en) * 2012-07-10 2014-01-16 Adispell, Inc. Anti-anxiety treatment
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited METHODS AND SYSTEMS FOR DRUG DELIVERY
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
KR102272452B1 (ko) 2020-12-11 2021-07-05 (주)예광솔라 스파이럴 파일 공법 및 이에 적용되는 스파이럴 파일
KR200497569Y1 (ko) 2021-02-18 2023-12-21 주식회사 알파인랩 지주 기초용 스크루 파일

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133073A (en) * 1959-12-10 1964-05-12 Sterling Drug Inc 3-aryl-1, 5-iminocycloalkanes and preparation thereof
US3657257A (en) * 1970-08-31 1972-04-18 Robins Co Inc A H 3-aryl-8-carbamoyl nortropanes
CA1244028A (en) 1983-04-14 1988-11-01 Hans Maag Pyrimidine derivatives
GB9019973D0 (en) 1990-09-12 1990-10-24 Wyeth John & Brother Ltd Azabicyclic derivatives
US5045546A (en) 1990-10-26 1991-09-03 Hoechst-Roussel Pharmaceuticals Inc. 8-azabicyclo[3.2.1]octylalkylthiazolidines
FI111367B (fi) 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
ES2153360T3 (es) * 1991-05-29 2001-03-01 Abbott Lab Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
JPH11512443A (ja) * 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
ATE362931T1 (de) * 1995-10-13 2007-06-15 Neurosearch As 8-azabicyclo(3.2.1)oct-2en-derivate, deren herstellung und anwendung
GB9706222D0 (en) * 1997-03-26 1997-05-14 Zeneca Ltd Bicyclic amine derivatives
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
CA2335336A1 (en) * 1998-06-19 1999-12-23 James Edmund Audia Inhibition of serotonin reuptake

Also Published As

Publication number Publication date
CN1157392C (zh) 2004-07-14
EP0984965B1 (en) 2004-05-19
HUP0002713A2 (hu) 2001-01-29
IL132437A (en) 2006-12-10
JP2002501514A (ja) 2002-01-15
JP4447663B2 (ja) 2010-04-07
CZ298824B6 (cs) 2008-02-20
ATE267199T1 (de) 2004-06-15
US20040019207A1 (en) 2004-01-29
CA2289574A1 (en) 1998-12-03
EE04057B1 (et) 2003-06-16
AU745964B2 (en) 2002-04-11
US6645977B1 (en) 2003-11-11
HUP0002713A3 (en) 2001-02-28
DE69823994T2 (de) 2009-09-24
EE9900529A (et) 2000-06-15
HK1027353A1 (en) 2001-01-12
IL132437A0 (en) 2001-03-19
CZ414799A3 (cs) 2000-02-16
TR199902942T2 (xx) 2000-04-21
EP0984965A1 (en) 2000-03-15
RU2186780C2 (ru) 2002-08-10
NZ500642A (en) 2001-11-30
IS2092B (is) 2006-04-12
CA2289574C (en) 2007-04-24
NO325513B1 (no) 2008-05-26
DE69823994D1 (de) 2004-06-24
SK284994B6 (sk) 2006-04-06
WO1998054181A1 (en) 1998-12-03
CN1257499A (zh) 2000-06-21
AU7426198A (en) 1998-12-30
US6964972B2 (en) 2005-11-15
SK162699A3 (en) 2000-07-11
DK0984965T3 (da) 2004-09-27
BR9809697A (pt) 2000-07-11
NO995850L (no) 1999-11-29
IS5243A (is) 1999-11-10
NO995850D0 (no) 1999-11-29
KR20010013154A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
KR100589872B1 (ko) 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
US6392045B1 (en) 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors
US6352995B1 (en) Spiro-quinuclidine derivatives, their preparation and use
AU747419B2 (en) Azaring-ether derivatives and their use as nicotinic ACH receptor modulators
US6420395B1 (en) Azacyclooctane and heptane derivatives, their preparation and use in therapy
MXPA99011081A (en) 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20100329

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110609

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110609